Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$20.6 million.

  • UroGen Pharma's Cash from Investing Activities rose 129.41% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 202.04%. This contributed to the annual value of -$20.6 million for FY2024, which is 2062.96% down from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Cash from Investing Activities is -$20.6 million, which was down 2,062.96% from -$953,000 recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Cash from Investing Activities peaked at $93.2 million during FY2020, and registered a low of -$20.6 million during FY2024.
  • For the 3-year period, UroGen Pharma's Cash from Investing Activities averaged around -$6.8 million, with its median value being -$953,000 (2023).
  • In the last 5 years, UroGen Pharma's Cash from Investing Activities spiked by 164.04% in 2020 and then slumped by 2,062.96% in 2024.
  • UroGen Pharma's Cash from Investing Activities (Yearly) stood at $93.2 million in 2020, then plummeted by 95.64% to $4.1 million in 2021, then tumbled by 73.95% to $1.1 million in 2022, then slumped by 189.91% to -$953,000 in 2023, then tumbled by 2,062.96% to -$20.6 million in 2024.